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Background

2. Department of Hematology and Cellular Therapy, Cedars Sinai Medical Center, Los Angeles, California

Study Objectives

Chimeric Antigen Receptor (CAR) T Cell Therapy is a type of immunotherapy in which
patients’ T-cells are collected and genetically modified with a retro/lentiviral vector ex-vivo
to express a CAR. All current FDA approved CARs are directed against the cell surface
antigens CD19 or BCMA which are expressed on B cells and plasma cells, respectively.
CAR T is indicated as a second line therapy for relapsed/refractory (r/r) large B cell
lymphoma (NHL), third-line therapy for acute lymphoblastic leukemia (ALL), and a fifth line
therapy for multiple myeloma (MM).
Preclinical data in mice demonstrate that myeloid cells work in concert with CAR
T-cells, increasing CAR T expansion in vivo and reducing tumor burden. Moreover, a
retrospective study in patients receiving axi-cel for NHL show that prolonged cytopenias
are associated with reduced CAR T efficacy. Addition of HSCs should help boost
hematopoietic recovery and hopefully, CAR T efficacy.
We designed a phase 1 single-arm, open-label study to evaluate the safety and
tolerability of autologous hematopoietic stem cells (HSCs) combined with CAR T-Cell
therapy in patients with r/r NHL, ALL, or MM.

Engineered Receptor Design

• The co-primary objective is:
→ To evaluate the safety and tolerability of autologous HSC
infusion shortly after CAR T

• The secondary objective is:
→ To evaluate the change in CAR T efficacy upon addition of
HSCs
→ This will be evaluated through CAR T expansion and
hematopoietic reserve post- HSC infusion (assessed using
the CAR-HEMATOTOX criteria)
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Discussions
Once this phase I, single center clinical trial at Cedars Sinai
Medical Center in Los Angeles, CA is activated later this year, we
plan to enroll 20 patients. In addition to our primary and secondary
objectives, we will explore the impacts of adding an auto-HSC
boost to the CAR T regimen on hematopoietic recovery,
inflammation, T-cell polyfunctionality, stem cell exhaustion, and
CAR T levels in blood. In all, we hope this trial will help improve
CAR T efficacy and reduce toxicity for patients in need.

Future Steps
•
•
•
•

Draft and submit and IRB project proposal.
Draft and submit IND to the U.S. Food and Drug Administration
Find, screen and enroll patients
Conduct trial
→ Treat patients, monitor safety and collect data

• Evaluate primary and secondary study objectives
Fusion protein
● T-cell costimulatory
receptor signaling
domain
● TCRζ activation
domain
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Activities
Clinical Trial
Documents
• Drafted the following:
• Clinical trial protocol
• informed consent
form draft
• Patient enrollment
plan for physicians
and clinical trial
team
• Guide for translating
clinical trial protocols

Working with a Clinical
Trial Team
• Worked with:
• Study sponsor / PI
• Cedars Sinai
Medical Center
SPIN group
• Pharmaceutical
company
representatives
• Biostatisticians
• Held regular meetings
and collaboratively
wrote and revised trial
documents

Educating Patients and
the Medical Community
on Cell Therapy
• Drafted informative
fliers to educate
patients on cell
therapy science,
procedures, and
clinical risks/benefits
• Created a plan to
educate physicians on
trial
• Presented clinical trial
to Hematology &
Cellular Therapy
Department

Primary Endpoint
o Assessing safety and tolerability through
collection of adverse events:
• Immune cell activation neurotoxicity
syndrome (ICANS)
• Cytokine release syndrome (CRS)
• Macrophage activation syndrome (MAS)
• Febrile neutropenia
• Cytopenia
• Infections

Secondary Endpoints
o Absolute neutrophil count (ANC)
recovery by Day 28
o Red blood cell and platelet
transfusion independence by Day 28
o Median progression free survival and
overall survival
o Days of hospitalization
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